Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants
dc.creator | Kuo, Tsun-Yung | |
dc.creator | Lien, Chia En | |
dc.creator | Lin, Yi-Jun | |
dc.creator | Lin, Meei-Yun | |
dc.creator | Liu, Luke Tzu-Chi | |
dc.creator | Wu, Chung-Chin | |
dc.creator | Tang, Wei-Hsuan | |
dc.creator | Chen, Charles | |
dc.date.accessioned | 2023-01-06T17:20:46Z | |
dc.date.available | 2023-01-06T17:20:46Z | |
dc.date.issued | 2022-10-07 | |
dc.identifier.doi | http://dx.doi.org/10.34944/dspace/8212 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12613/8241 | |
dc.description.abstract | The dominance of SARS-CoV-2 variants of concern (VoC), such as the Omicron subvariants, is a threat to the current vaccination scheme due to increased resistance to immune neutralization and greater transmissibility. To develop the next generation of prefusion SARS-CoV-2 spike protein (S-2P) subunit vaccine adjuvanted with CpG1018 and aluminum hydroxide, mice immunized with two doses of the adjuvanted ancestral Wuhan strain (W) followed by the third dose of the W or Omicron variants (BA.1 or BA.4/BA.5) S-2P, or a combination of the above bivalent S-2Ps. Antisera from mice were tested against pseudovirus neutralization assay of ancestral SARS-CoV-2 (WT) and Omicron BA.4/BA.5 subvariant. Boosting with bivalent mixture of Omicron BA.4/BA.5 and W S-2P achieved the highest neutralizing antibody titers against BA.4/BA.5 subvariant pseudovirus compared to other types of S-2P as boosters. | |
dc.format.extent | 11 pages | |
dc.language | English | |
dc.language.iso | eng | |
dc.relation.ispartof | Faculty/Researcher Works | |
dc.relation.isreferencedby | bioRxiv | |
dc.rights | Attribution-NonCommercial-NoDerivs CC BY-NC-ND | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Immunology | |
dc.title | Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants | |
dc.type | Text | |
dc.type.genre | Pre-print | |
dc.description.department | Biology | |
dc.relation.doi | https://doi.org/10.1101/2022.10.07.511263 | |
dc.ada.note | For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu | |
dc.description.schoolcollege | Temple University. College of Science and Technology | |
dc.temple.creator | Chen, Charles | |
refterms.dateFOA | 2023-01-06T17:20:46Z |